NEVRO CORP

 NVROのチャート


 NVROの企業情報

symbol NVRO
会社名 Nevro Corp (NEVRO CORP)
分野(sector)   
産業(industry)   
業種 医療機器_医療用品_ディストリビュ―タ―   医療関連(Health Care)
概要 ネブロ(Nevro Corp)は医療機器の提供者である。同社は慢性疼痛患者の生活の質を改善する製品を提供することに重点を置く。同社は慢性疼痛の治療のための神経調節プラットフォームであるSenza脊髄電気刺激(SCS)システムを開発・商品化する。同社のHF10療法は慢性疼痛の治療のための神経調節溶液を送達するように設計される。HF10療法は患者が異常感覚を伴わずに持続的鎮痛軽減を達成することを可能にし、不快なショッキングまたは激しい感覚を避けることができる。HF10療法は解剖学的リードの配置に依存する。Senzaシステムは2ヘルツ(Hz)から10000 Hzまでの電気インパルスを生成する。  ネブロは、米国の医療機器メ―カ―。慢性疼痛の治療のための神経調節プラットフォ―ムを開発し、商品化。同社の製品「SENZA」システムは、HF10治療を提供する脊髄刺激(SCS)システムである。SENZAは、10kHzの波形刺激を出すHF10治療に加え、2Hzから10kHzの電気刺激が出るように設計。感覚異常を起こさずに痛みを軽減する。  Nevro Corp. engages in the provision of medical devices. The firm focuses on providing products that improve the quality of life of patients suffering from debilitating chronic pain. It develops and commercializes senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company was founded by Konstantinos Alataris in March 2006 and is headquartered in Redwood City, CA.
本社所在地 1800 Bridge Parkway Redwood City CA 94065 USA
代表者氏名 D.Keith Grossman
代表者役職名 President Chief Executive Officer Director
電話番号 +1 650-251-0005
設立年月日 38777
市場名 NYSE(ニューヨーク証券取引所)
ipoyear
従業員数 804人
url www.nevro.com
nasdaq_url
adr_tso
EBITDA (百万ドル) -37.85600
終値(lastsale)
時価総額(marketcap)
時価総額 (百万ドル) 1949.35500
売上高 (百万ドル) 387.28900
企業価値(EV) (百万ドル) 1837.20200
当期純利益 (百万ドル) -49.20500
決算概要 BRIEF: For the fiscal year ended 31 December 2018 Nevro Corp revenues increased 19% to $387.3M. Net loss increased 34% to $49.2M. Revenues reflect United States segment increase of 22% to $321.8M. Higher net loss reflects Selling/General/Admin. Expense - Balanci increase of 19% to $238.5M (expense) Research and Development Expense - Bal increase of 29% to $42.6M (expense).

 NVROのテクニカル分析


 NVROのニュース

   Nevro Announces Third Quarter 2020 Financial Results  2020/11/05 21:02:00 PR Newswire
REDWOOD CITY, Calif., Nov. 5, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced its financial results for the third quarter ended September 30, 2020….
   Nevro Earnings Scorecard & Analyst Reports Stock market Insights & financial analysis  2020/11/05 15:52:00 Stock Market Daily
Nevro announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Neurostimulation Devices Market Top Key Players- Medtronic plc, NeuroPace Inc., Nevro Corporation, Neuronetics Inc. Growth Trends, quantitative analysis Industry Analysis and Market Dynamics of the Global Market, 2020 to 2027  2020/10/27 11:13:54 OpenPR
Summary of the Neurostimulation Devices Market Report Due to the various economic, technological, research & development and geographical aspects, the Neurostimulation Devices Market would gain a healthy CAGR and market size from 2020 to 2027. The growth trend would continue to
   Neurostimulation Devices Market Top Key Players- Nevro Corporation, Neuronetics Inc., NeuroSigma, Inc., Synapse Biomedical Inc Growth Trends, quantitative analysis Industry Analysis and Market Dynamics of the Global Market, 2020 to 2027  2020/10/27 11:08:42 OpenPR
Summary of the Neurostimulation Devices Market Report Due to the various economic, technological, research & development and geographical aspects, the Neurostimulation Devices Market would gain a healthy CAGR and market size from 2020 to 2027. The growth trend would
   Nevro (NYSE:NVRO) Raised to “Positive” at OTR Global  2020/10/24 06:44:49 Stock Observer
OTR Global upgraded shares of Nevro (NYSE:NVRO) to a positive rating in a research report report published on Wednesday morning, The Fly reports. Several other research firms have also recently commented on NVRO. Oppenheimer initiated coverage on Nevro in a research note on Wednesday, August 5th. They issued a hold rating on the stock. SVB […]
   Nevro Announces Third Quarter 2020 Financial Results  2020/11/05 21:02:00 PR Newswire
REDWOOD CITY, Calif., Nov. 5, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced its financial results for the third quarter ended September 30, 2020….
   Nevro Earnings Scorecard & Analyst Reports Stock market Insights & financial analysis  2020/11/05 15:52:00 Stock Market Daily
Nevro announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Neurostimulation Devices Market Top Key Players- Medtronic plc, NeuroPace Inc., Nevro Corporation, Neuronetics Inc. Growth Trends, quantitative analysis Industry Analysis and Market Dynamics of the Global Market, 2020 to 2027  2020/10/27 11:13:54 OpenPR
Summary of the Neurostimulation Devices Market Report Due to the various economic, technological, research & development and geographical aspects, the Neurostimulation Devices Market would gain a healthy CAGR and market size from 2020 to 2027. The growth trend would continue to
   Neurostimulation Devices Market Top Key Players- Nevro Corporation, Neuronetics Inc., NeuroSigma, Inc., Synapse Biomedical Inc Growth Trends, quantitative analysis Industry Analysis and Market Dynamics of the Global Market, 2020 to 2027  2020/10/27 11:08:42 OpenPR
Summary of the Neurostimulation Devices Market Report Due to the various economic, technological, research & development and geographical aspects, the Neurostimulation Devices Market would gain a healthy CAGR and market size from 2020 to 2027. The growth trend would
   Nevro (NYSE:NVRO) Raised to “Positive” at OTR Global  2020/10/24 06:44:49 Stock Observer
OTR Global upgraded shares of Nevro (NYSE:NVRO) to a positive rating in a research report report published on Wednesday morning, The Fly reports. Several other research firms have also recently commented on NVRO. Oppenheimer initiated coverage on Nevro in a research note on Wednesday, August 5th. They issued a hold rating on the stock. SVB […]
   Analysts Anticipate Nevro Corp. (NYSE:NVRO) Will Post Quarterly Sales of $103.56 Million  2020/10/20 16:58:42 Transcript Daily
Equities research analysts predict that Nevro Corp. (NYSE:NVRO) will announce $103.56 million in sales for the current quarter, Zacks Investment Research reports. Six analysts have issued estimates for Nevro’s earnings, with the lowest sales estimate coming in at $102.90 million and the highest estimate coming in at $105.00 million. Nevro posted sales of $100.16 million […]
   Zacks: Brokerages Expect Nevro Corp. (NYSE:NVRO) Will Post Earnings of -$0.58 Per Share  2020/10/20 16:58:42 Transcript Daily
Brokerages predict that Nevro Corp. (NYSE:NVRO) will report earnings per share (EPS) of ($0.58) for the current quarter, according to Zacks. Six analysts have issued estimates for Nevro’s earnings. The lowest EPS estimate is ($0.94) and the highest is ($0.39). Nevro also posted earnings per share of ($0.58) in the same quarter last year. The […]
   Liberty All-Star® Growth Fund, Inc. September 2020 Monthly Update  2020/10/15 17:41:00 Benzinga
BOSTON , Oct. 15, 2020 /PRNewswire/ -- Below is the September 2020 Monthly Update for the Liberty All-Star Growth Fund, Inc. (NYSE: ASG ) Liberty All-Star Growth Fund, Inc. Ticker: ASG Monthly Update, September, 2020 Investment Approach: Fund Style: All-Cap Growth Fund Strategy: Combines three growth style investment managers, each with a distinct capitalization focus (small-, mid- and large-cap) selected and continuously monitored by the Fund's Investment Advisor. Investment Managers: Weatherbie Capital, LLC Small-Cap Growth Congress Asset Management Company, LLP Mid-Cap Growth Sustainable Growth Advisers, LP Large-Cap Growth Top 20 Holdings at Month-End (31.5% of equity portfolio) 1 FirstService Corp. 2.1% 2 Chegg, Inc. 2.0% 3 Paylocity Holding Corp. 1.9% 4 Nevro Corp. 1.9% 5 Microsoft Corp. 1.7% 6 Visa, Inc. 1.7% 7 Progyny, Inc. 1.6% 8 Amazon.com, Inc. Full story available on Benzinga.com
   The Daily Biotech Pulse: Vertex Pulls Plug On Protein Deficiency Drug, FDA Nod For Regeneron's Ebola Treatment, Can Fite Issues Psoriasis Readout  2020/10/15 12:03:43 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 14) 10X Genomics Inc (NASDAQ: TXG ) Aileron Therapeutics Inc (NASDAQ: ALRN ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) Blueprint Medicines Corp (NASDAQ: BPMC ) Calliditas Therapeutics Adr Rep 2 Ord Shs (NASDAQ: CALT ) Cellectis SA (NASDAQ: CLLS ) Crispr Therapeutics AG (NASDAQ: CRSP ) Denali Therapeutics Inc (NASDAQ: DNLI ) Immunomedics, Inc (NASDAQ: IMMU ) - The Hart-Scott-Rodino waiting period for its impending acquisition by Gilead Sciences, Inc. (NASDAQ: GILD ) expired, meeting one of the conditions necessary for the consummation of the transaction Insulet Corporation (NASDAQ: PODD ) Kronos Bio Inc (NASDAQ: KRON ) (went public Friday) Kura Oncology Inc (NASDAQ: KURA ) Kymera Therapeutics Inc (NASDAQ: KYMR ) Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) Mirati Therapeutics Inc (NASDAQ: MRTX ) NeoGenomics, Inc (NASDAQ: NEO ) Nevro Corp (NYSE: NVRO ) Novocure Ltd (NASDAQ: NVCR ) Ocular Therapeutix Inc (NASDAQ: OCUL ) Oncorus Inc (NASDAQ: ONCR ) Pacific Biosciences of California Inc (NASDAQ: PACB ) PRA Health Sciences Inc (NASDAQ: PRAH ) Replimune Group Inc (NASDAQ: REPL ) (abstract comprising data for its lead candidate RP1 in advanced solid tumors to be presented at the November Society for Immunotherapy of Cancer annual meeting made available online) Seres Therapeutics Inc (NASDAQ: MCRB ) SpringWorks Therapeutics Inc (NASDAQ: Full story available on Benzinga.
   The Daily Biotech Pulse: J&J Pauses Coronavirus Vaccine Studies, Voyager's Huntington's Disease Study Placed On Hold, Altimmune Vaccine Data  2020/10/13 12:20:13 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 12) 10X Genomics Inc (NASDAQ: TXG ) Acceleron Pharma Inc (NASDAQ: XLRN ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) argenx SE – ADR (NASDAQ: ARGX ) Beigene Ltd (NASDAQ: BGNE ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Blueprint Medicines Corp (NASDAQ: BPMC ) Calliditas Therapeutics Adr Rep 2 Ord Shs (NASDAQ: CALT ) Cardiff Oncology Inc (NASDAQ: CRDF ) CareDx Inc (NASDAQ: CDNA ) Castle Biosciences Inc (NASDAQ: CSTL ) Denali Therapeutics Inc (NASDAQ: DNLI ) Fate Therapeutics Inc (NASDAQ: FATE ) Immunovant Inc (NASDAQ: IMVT ) Insmed Incorporated (NASDAQ: INSM ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Kronos Bio Inc (NASDAQ: KRON ) (went public Friday) Kura Oncology Inc (NASDAQ: KURA ) Kymera Therapeutics Inc (NASDAQ: KYMR ) Lantern Pharma Inc.

 関連キーワード  (医療機器_医療用品_ディストリビュ―タ― 米国株 NEVRO CORP NVRO )

医療で使われる機器のこと。レントゲン装置やからだの断面を画像化できるMRI(磁気共鳴画像)装置など高機能機器を含め数多くの種類がある。医療現場で使われるため、正確で精密である点などが求められる。医療機器への需要は着実に高まっており、電機メーカーなどからの進出も進んでいる。

 twitter  (公式ツイッターやCEOツイッターなど)